Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer

Affiliations

• ¹ Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ² Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ³ Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
• ⁴ Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ⁵ Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
• ⁶ Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.
• ⁷ Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
• ⁸ Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
• ⁹ Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France.
• ¹⁰ Bioinformatics Institute (A*STAR), Singapore, Singapore.
• ¹¹ Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
• ¹² The Breast Cancer Now Research Centre, London, UK.
• ¹³ Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK.
• ¹⁴ Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
• ¹⁵ Novartis Pharmaceuticals, East Hanover, NJ, USA.
• ¹⁶ Genentech, Inc., South San Francisco, California, USA.
• ¹⁷ Breast Biology Group, Manchester Breast Centre, Manchester, UK.
• ¹⁸ Cancer Research UK, Cambridge, UK.
• ¹⁹ CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ²⁰ Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ²¹ Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
• ²² IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
• ²³ Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
• ²⁴ University of Barcelona, Barcelona, Spain.
• ²⁵ Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
• ²⁶ SOLTI Breast Cancer Research Group, Barcelona, Spain.
• ²⁷ Department of Oncology, IOB Institute of Oncology, Barcelona, Spain.
• ²⁸ Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ²⁹ School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
• ³⁰ Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
• ³¹ Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.
• ³² Department of Medical Oncology, Gustave Roussy, Villejuif, France.
• ³³ Inserm Unit U981, Villejuif, France.
• ³⁴ Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. [email protected].
• ³⁵ CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain. [email protected].